Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>Addressing skeptics of CYB003’s durability data. As impressive as CYB003’s Phase 2 12-month data are, not everyone fully embraces them because of the small population size (n=7) from which they were generated.</li><li>While this may logically be a fair question, Inamdar addressed this question by stating that not all data are created equal, with some data more impactful than others.</li><li>Even with small numbers, you can have highly impactful data, and CYB003’s data were highly impactful clinically with a 100% response rate, a 70%-plus remission rate, and a mean 23-point MADRS change from baseline versus the two to three-point change that is typically considered by experts to be clinically significant outcomes for depression.</li></ul>

Addressing skeptics of CYB003’s durability data. As impressive as CYB003’s Phase 2 12-month data are, not everyone fully embraces them because of the small population size (n=7) from which they were generated.While this may logically be a fair question, Inamdar addressed this question by stating that not all data are created equal, with some data more impactful than others.Even with small numbers, you can have highly impactful data, and CYB003’s data were highly impactful clinically with a 100% response rate, a 70%-plus remission rate, and a mean 23-point MADRS change from baseline versus the two to three-point change that is typically considered by experts to be clinically significant outcomes for depression.

Cybin, Inc. - First Dosing of Meticulously Planned CYB003 Phase 3 Program Imminent